Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project.